CN104804001B9 - 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 - Google Patents
4-取代吡咯并[2,3-d]嘧啶化合物及其用途 Download PDFInfo
- Publication number
- CN104804001B9 CN104804001B9 CN201410036561.7A CN201410036561A CN104804001B9 CN 104804001 B9 CN104804001 B9 CN 104804001B9 CN 201410036561 A CN201410036561 A CN 201410036561A CN 104804001 B9 CN104804001 B9 CN 104804001B9
- Authority
- CN
- China
- Prior art keywords
- compound
- drying
- formula
- pyrrolo
- acetonitrile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 4-substituted pyrrolo [2,3-d ] pyrimidine compounds Chemical class 0.000 title abstract description 20
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 239000003814 drug Substances 0.000 claims abstract description 19
- 239000000126 substance Substances 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 10
- 238000006243 chemical reaction Methods 0.000 claims description 62
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 15
- 150000001924 cycloalkanes Chemical class 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 125000005843 halogen group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 102000042838 JAK family Human genes 0.000 claims description 7
- 108091082332 JAK family Proteins 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 150000002431 hydrogen Chemical group 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 3
- 230000003287 optical effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000006467 substitution reaction Methods 0.000 claims description 3
- 229940126062 Compound A Drugs 0.000 claims description 2
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003054 catalyst Substances 0.000 claims description 2
- JNGZXGGOCLZBFB-IVCQMTBJSA-N compound E Chemical compound N([C@@H](C)C(=O)N[C@@H]1C(N(C)C2=CC=CC=C2C(C=2C=CC=CC=2)=N1)=O)C(=O)CC1=CC(F)=CC(F)=C1 JNGZXGGOCLZBFB-IVCQMTBJSA-N 0.000 claims description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
- 125000006239 protecting group Chemical group 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- 230000000259 anti-tumor effect Effects 0.000 claims 1
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 12
- 230000005764 inhibitory process Effects 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 5
- 102000001253 Protein Kinase Human genes 0.000 abstract description 4
- 108060006633 protein kinase Proteins 0.000 abstract description 4
- 230000004663 cell proliferation Effects 0.000 abstract description 2
- 208000026278 immune system disease Diseases 0.000 abstract description 2
- 238000001035 drying Methods 0.000 description 73
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 37
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 36
- 230000015572 biosynthetic process Effects 0.000 description 34
- 238000003786 synthesis reaction Methods 0.000 description 34
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 29
- 239000002994 raw material Substances 0.000 description 27
- 238000000605 extraction Methods 0.000 description 26
- 238000003756 stirring Methods 0.000 description 24
- 239000012043 crude product Substances 0.000 description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 239000012074 organic phase Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 17
- 239000012265 solid product Substances 0.000 description 16
- 229910052757 nitrogen Inorganic materials 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 12
- 238000010791 quenching Methods 0.000 description 12
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000007858 starting material Substances 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 230000000171 quenching effect Effects 0.000 description 10
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 125000004567 azetidin-3-yl group Chemical group N1CC(C1)* 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000001376 precipitating effect Effects 0.000 description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 5
- 150000001336 alkenes Chemical class 0.000 description 5
- 238000010828 elution Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- KWMBADTWRIGGGG-UHFFFAOYSA-N 2-diethoxyphosphorylacetonitrile Chemical compound CCOP(=O)(CC#N)OCC KWMBADTWRIGGGG-UHFFFAOYSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 229910052593 corundum Inorganic materials 0.000 description 4
- 238000007865 diluting Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- VMKIXWAFFVLJCK-UHFFFAOYSA-N tert-butyl 3-oxoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(=O)C1 VMKIXWAFFVLJCK-UHFFFAOYSA-N 0.000 description 4
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229910001845 yogo sapphire Inorganic materials 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000002355 alkine group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 125000006125 ethylsulfonyl group Chemical group 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000009822 protein phosphorylation Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 235000017550 sodium carbonate Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- WORJRXHJTUTINR-UHFFFAOYSA-N 1,4-dioxane;hydron;chloride Chemical class Cl.C1COCCO1 WORJRXHJTUTINR-UHFFFAOYSA-N 0.000 description 2
- QKPZELKXOODYOU-UHFFFAOYSA-N 2-[3-[5,7-difluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-ethylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C(F)=CC(F)=C2)C1=C2C=CNC2=NC=N1 QKPZELKXOODYOU-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- 102000008986 Janus Human genes 0.000 description 2
- 108050000950 Janus Proteins 0.000 description 2
- 108010024121 Janus Kinases Proteins 0.000 description 2
- 102000015617 Janus Kinases Human genes 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 2
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000018937 joint inflammation Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000009987 spinning Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- YAJAHJHIYRKRKH-UHFFFAOYSA-N 2-[1-(azepane-2-carbonyl)-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=C(C1CCCCCN1)N1CC(CC#N)(C1)N1C=C(C2=C1C=CC=C2)C1=C2C=CNC2=NC=N1 YAJAHJHIYRKRKH-UHFFFAOYSA-N 0.000 description 1
- NUYPZKZQLOZPLA-UHFFFAOYSA-N 2-[1-(oxepane-2-carbonyl)-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound N1=CN=C(C2=C1NC=C2)C1=CN(C2=CC=CC=C12)C1(CN(C1)C(=O)C1OCCCCC1)CC#N NUYPZKZQLOZPLA-UHFFFAOYSA-N 0.000 description 1
- DFPPVJNAJYADAM-UHFFFAOYSA-N 2-[1-butylsulfonyl-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CCCCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=CC=C2)C1=C2C=CNC2=NC=N1 DFPPVJNAJYADAM-UHFFFAOYSA-N 0.000 description 1
- NRLJPQFXDKBMRN-UHFFFAOYSA-N 2-[1-cyclopropylsulfonyl-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound O=S(=O)(C1CC1)N1CC(CC#N)(C1)N1C=C(C2=C1C=CC=C2)C1=C2C=CNC2=NC=N1 NRLJPQFXDKBMRN-UHFFFAOYSA-N 0.000 description 1
- NANOUGWOCMXWOU-UHFFFAOYSA-N 2-[1-cyclopropylsulfonyl-3-[5,6-difluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC2=C(C=C1F)C(=CN2C1(CC#N)CN(C1)S(=O)(=O)C1CC1)C1=C2C=CNC2=NC=N1 NANOUGWOCMXWOU-UHFFFAOYSA-N 0.000 description 1
- YGMYDGRSGCICRA-UHFFFAOYSA-N 2-[1-cyclopropylsulfonyl-3-[6,7-difluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=C(F)C2=C(C=C1)C(=CN2C1(CC#N)CN(C1)S(=O)(=O)C1CC1)C1=C2C=CNC2=NC=N1 YGMYDGRSGCICRA-UHFFFAOYSA-N 0.000 description 1
- PIRDYOGVFKBUKB-UHFFFAOYSA-N 2-[1-cyclopropylsulfonyl-3-[6-fluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound FC1=CC2=C(C=C1)C(=CN2C1(CC#N)CN(C1)S(=O)(=O)C1CC1)C1=C2C=CNC2=NC=N1 PIRDYOGVFKBUKB-UHFFFAOYSA-N 0.000 description 1
- ALEMQFKPROZQHR-UHFFFAOYSA-N 2-[1-ethylsulfonyl-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-6-(trifluoromethyl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound C(C)S(=O)(=O)N1CC(C1)(N1C=C(C2=CC=C(C=C12)C(F)(F)F)C=1C2=C(N=CN=1)NC=C2)CC#N ALEMQFKPROZQHR-UHFFFAOYSA-N 0.000 description 1
- GCPYYJXTLXBXJU-UHFFFAOYSA-N 2-[1-ethylsulfonyl-3-[6-methoxy-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(OC)C=C2)C1=C2C=CNC2=NC=N1 GCPYYJXTLXBXJU-UHFFFAOYSA-N 0.000 description 1
- OPSDIKZKVRNJTL-UHFFFAOYSA-N 2-[1-ethylsulfonyl-3-[6-methyl-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(C)C=C2)C1=C2C=CNC2=NC=N1 OPSDIKZKVRNJTL-UHFFFAOYSA-N 0.000 description 1
- AOXKDZCNRSDEQT-UHFFFAOYSA-N 2-[1-ethylsulfonyl-3-[6-propan-2-yl-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(C=C2)C(C)C)C1=C2C=CNC2=NC=N1 AOXKDZCNRSDEQT-UHFFFAOYSA-N 0.000 description 1
- DEYLLAMESFTYRA-UHFFFAOYSA-N 2-[1-ethylsulfonyl-3-[6-propan-2-yloxy-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(OC(C)C)C=C2)C1=C2C=CNC2=NC=N1 DEYLLAMESFTYRA-UHFFFAOYSA-N 0.000 description 1
- FYPPWZHRVUTBIG-UHFFFAOYSA-N 2-[1-ethylsulfonyl-3-[6-propoxy-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CCCOC1=CC2=C(C=C1)C(=CN2C1(CC#N)CN(C1)S(=O)(=O)CC)C1=C2C=CNC2=NC=N1 FYPPWZHRVUTBIG-UHFFFAOYSA-N 0.000 description 1
- HMBMXHXEUNDXNQ-UHFFFAOYSA-N 2-[1-ethylsulfonyl-3-[6-propyl-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CCCC1=CC2=C(C=C1)C(=CN2C1(CC#N)CN(C1)S(=O)(=O)CC)C1=C2C=CNC2=NC=N1 HMBMXHXEUNDXNQ-UHFFFAOYSA-N 0.000 description 1
- CKOFSWJPSPEDFO-UHFFFAOYSA-N 2-[1-methylsulfonyl-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=CC=C2)C1=C2C=CNC2=NC=N1 CKOFSWJPSPEDFO-UHFFFAOYSA-N 0.000 description 1
- KTOHRCMHWZFBRU-UHFFFAOYSA-N 2-[1-propan-2-ylsulfonyl-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CC(C)S(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=CC=C2)C1=C2C=CNC2=NC=N1 KTOHRCMHWZFBRU-UHFFFAOYSA-N 0.000 description 1
- LSCRCPBEVOGIBN-UHFFFAOYSA-N 2-[1-propylsulfonyl-3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]azetidin-3-yl]acetonitrile Chemical compound CCCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=CC=C2)C1=C2C=CNC2=NC=N1 LSCRCPBEVOGIBN-UHFFFAOYSA-N 0.000 description 1
- ZUZIKYDBXDBVRH-UHFFFAOYSA-N 2-[3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-(thiane-2-carbonyl)azetidin-3-yl]acetonitrile Chemical compound O=C(C1CCCCS1)N1CC(CC#N)(C1)N1C=C(C2=C1C=CC=C2)C1=C2C=CNC2=NC=N1 ZUZIKYDBXDBVRH-UHFFFAOYSA-N 0.000 description 1
- LGWGPWKOHYSMGW-UHFFFAOYSA-N 2-[3-[3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-(thiepane-2-carbonyl)azetidin-3-yl]acetonitrile Chemical compound O=C(C1CCCCCS1)N1CC(CC#N)(C1)N1C=C(C2=C1C=CC=C2)C1=C2C=CNC2=NC=N1 LGWGPWKOHYSMGW-UHFFFAOYSA-N 0.000 description 1
- WLSZKWGHMGBJDO-UHFFFAOYSA-N 2-[3-[5,6-difluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-ethylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(F)C(F)=C2)C1=C2C=CNC2=NC=N1 WLSZKWGHMGBJDO-UHFFFAOYSA-N 0.000 description 1
- VCGVNNHWEUQRDP-UHFFFAOYSA-N 2-[3-[5,6-difluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-methylsulfonylazetidin-3-yl]acetonitrile Chemical compound CS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(F)C(F)=C2)C1=C2C=CNC2=NC=N1 VCGVNNHWEUQRDP-UHFFFAOYSA-N 0.000 description 1
- IADOIDLRVXGOAT-UHFFFAOYSA-N 2-[3-[5,6-difluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-propylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(F)C(F)=C2)C1=C2C=CNC2=NC=N1 IADOIDLRVXGOAT-UHFFFAOYSA-N 0.000 description 1
- DJQIKXHLDMUUJI-UHFFFAOYSA-N 2-[3-[6,7-difluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-ethylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C(F)=C(F)C=C2)C1=C2C=CNC2=NC=N1 DJQIKXHLDMUUJI-UHFFFAOYSA-N 0.000 description 1
- XDCAOZQRUMMHFU-UHFFFAOYSA-N 2-[3-[6,7-difluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-methylsulfonylazetidin-3-yl]acetonitrile Chemical compound CS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C(F)=C(F)C=C2)C1=C2C=CNC2=NC=N1 XDCAOZQRUMMHFU-UHFFFAOYSA-N 0.000 description 1
- KIBFXKQPFIWYCU-UHFFFAOYSA-N 2-[3-[6,7-difluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-propylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C(F)=C(F)C=C2)C1=C2C=CNC2=NC=N1 KIBFXKQPFIWYCU-UHFFFAOYSA-N 0.000 description 1
- RYLIMASHJSHOEJ-UHFFFAOYSA-N 2-[3-[6-bromo-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-ethylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(Br)C=C2)C1=C2C=CNC2=NC=N1 RYLIMASHJSHOEJ-UHFFFAOYSA-N 0.000 description 1
- JDTRDEZCVCQPAM-UHFFFAOYSA-N 2-[3-[6-bromo-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-methylsulfonylazetidin-3-yl]acetonitrile Chemical compound CS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(Br)C=C2)C1=C2C=CNC2=NC=N1 JDTRDEZCVCQPAM-UHFFFAOYSA-N 0.000 description 1
- BQORUGGDBWCWOU-UHFFFAOYSA-N 2-[3-[6-chloro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-cyclopropylsulfonylazetidin-3-yl]acetonitrile Chemical compound ClC1=CC2=C(C=C1)C(=CN2C1(CC#N)CN(C1)S(=O)(=O)C1CC1)C1=C2C=CNC2=NC=N1 BQORUGGDBWCWOU-UHFFFAOYSA-N 0.000 description 1
- AWASANQHPPBWPD-UHFFFAOYSA-N 2-[3-[6-chloro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-ethylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(Cl)C=C2)C1=C2C=CNC2=NC=N1 AWASANQHPPBWPD-UHFFFAOYSA-N 0.000 description 1
- UMYIECCOJWBGPK-UHFFFAOYSA-N 2-[3-[6-chloro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-methylsulfonylazetidin-3-yl]acetonitrile Chemical compound CS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(Cl)C=C2)C1=C2C=CNC2=NC=N1 UMYIECCOJWBGPK-UHFFFAOYSA-N 0.000 description 1
- BSTARSFWZVGUEI-UHFFFAOYSA-N 2-[3-[6-chloro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-propan-2-ylsulfonylazetidin-3-yl]acetonitrile Chemical compound CC(C)S(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(Cl)C=C2)C1=C2C=CNC2=NC=N1 BSTARSFWZVGUEI-UHFFFAOYSA-N 0.000 description 1
- FZPFSHUHQSSMQA-UHFFFAOYSA-N 2-[3-[6-chloro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-propylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(Cl)C=C2)C1=C2C=CNC2=NC=N1 FZPFSHUHQSSMQA-UHFFFAOYSA-N 0.000 description 1
- XVHXFURPAXUFFS-UHFFFAOYSA-N 2-[3-[6-ethoxy-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-ethylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCOC1=CC2=C(C=C1)C(=CN2C1(CC#N)CN(C1)S(=O)(=O)CC)C1=C2C=CNC2=NC=N1 XVHXFURPAXUFFS-UHFFFAOYSA-N 0.000 description 1
- IJKXKXFHUDGAQS-UHFFFAOYSA-N 2-[3-[6-ethyl-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-ethylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCC1=CC2=C(C=C1)C(=CN2C1(CC#N)CN(C1)S(=O)(=O)CC)C1=C2C=CNC2=NC=N1 IJKXKXFHUDGAQS-UHFFFAOYSA-N 0.000 description 1
- ILXDYMIFTJMDED-UHFFFAOYSA-N 2-[3-[6-fluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-methylsulfonylazetidin-3-yl]acetonitrile Chemical compound CS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(F)C=C2)C1=C2C=CNC2=NC=N1 ILXDYMIFTJMDED-UHFFFAOYSA-N 0.000 description 1
- WDYZZLVTBAXTBB-UHFFFAOYSA-N 2-[3-[6-fluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-propan-2-ylsulfonylazetidin-3-yl]acetonitrile Chemical compound CC(C)S(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(F)C=C2)C1=C2C=CNC2=NC=N1 WDYZZLVTBAXTBB-UHFFFAOYSA-N 0.000 description 1
- GNKCPVWTYZOUKV-UHFFFAOYSA-N 2-[3-[6-fluoro-3-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)indol-1-yl]-1-propylsulfonylazetidin-3-yl]acetonitrile Chemical compound CCCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C2=C1C=C(F)C=C2)C1=C2C=CNC2=NC=N1 GNKCPVWTYZOUKV-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 238000011763 DBA/1J (JAX™ mouse strain) Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 108010029477 STAT5 Transcription Factor Proteins 0.000 description 1
- 102100024481 Signal transducer and activator of transcription 5A Human genes 0.000 description 1
- 241000009334 Singa Species 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940100514 Syk tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000004012 Tofacitinib Substances 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 150000001345 alkine derivatives Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940114081 cinnamate Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical class [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 230000031146 intracellular signal transduction Effects 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- JFCHSQDLLFJHOA-UHFFFAOYSA-N n,n-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 150000003335 secondary amines Chemical group 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960001350 tofacitinib Drugs 0.000 description 1
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M trans-cinnamate Chemical compound [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-M vanillate Chemical compound COC1=CC(C([O-])=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-M 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
实施例编号 | 化学结构式 | 化学名 | 制备方法 |
Claims (10)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410036561.7A CN104804001B9 (zh) | 2014-01-24 | 2014-01-24 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
US15/112,196 US10385056B2 (en) | 2014-01-24 | 2015-03-24 | 4-substituted pyrrolo[2,3-d]pyrimidine compound and use thereof |
PCT/CN2015/074989 WO2015110092A1 (zh) | 2014-01-24 | 2015-03-24 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410036561.7A CN104804001B9 (zh) | 2014-01-24 | 2014-01-24 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
Publications (3)
Publication Number | Publication Date |
---|---|
CN104804001A CN104804001A (zh) | 2015-07-29 |
CN104804001B CN104804001B (zh) | 2017-09-12 |
CN104804001B9 true CN104804001B9 (zh) | 2022-02-08 |
Family
ID=53680855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410036561.7A Active CN104804001B9 (zh) | 2014-01-24 | 2014-01-24 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
Country Status (3)
Country | Link |
---|---|
US (1) | US10385056B2 (zh) |
CN (1) | CN104804001B9 (zh) |
WO (1) | WO2015110092A1 (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105541891B (zh) * | 2016-02-04 | 2017-11-28 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
CN112225739B (zh) * | 2019-07-15 | 2024-04-26 | 宜昌东阳光制药有限公司 | 一种氮杂环丁烷化合物的制备方法 |
CN111704617B (zh) * | 2020-06-15 | 2022-08-23 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1518552A (zh) * | 2001-06-23 | 2004-08-04 | ����˹��ҩ�﹫˾ | 作为蛋白激酶抑制剂的吡咯并嘧啶 |
WO2012068450A1 (en) * | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
-
2014
- 2014-01-24 CN CN201410036561.7A patent/CN104804001B9/zh active Active
-
2015
- 2015-03-24 WO PCT/CN2015/074989 patent/WO2015110092A1/zh active Application Filing
- 2015-03-24 US US15/112,196 patent/US10385056B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1518552A (zh) * | 2001-06-23 | 2004-08-04 | ����˹��ҩ�﹫˾ | 作为蛋白激酶抑制剂的吡咯并嘧啶 |
WO2012068450A1 (en) * | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
Also Published As
Publication number | Publication date |
---|---|
WO2015110092A1 (zh) | 2015-07-30 |
US10385056B2 (en) | 2019-08-20 |
CN104804001A (zh) | 2015-07-29 |
US20160333015A1 (en) | 2016-11-17 |
CN104804001B (zh) | 2017-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104230827B (zh) | 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮作为parp抑制剂及其应用 | |
CN109906227A (zh) | 8,9-二氢咪唑[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮类化合物 | |
WO2015073763A1 (en) | Substituted 4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine derivatives as casein kinase 1 d/e inhibitors | |
CA2864672C (en) | Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme | |
EP3157925A1 (en) | Imidazo-pyridazne derivatives as casein kinase 1 delta/epsilon inhibitors | |
JP2010524911A (ja) | 5−アミノピラゾール−3−イル−3H−イミダゾ[4,5−b]ピリジン誘導体と癌の治療のためのその使用 | |
JP7384535B2 (ja) | キナゾリン化合物並びにその調製方法、使用及び医薬組成物 | |
JP2017513847A (ja) | 2,3,4,6−4置換ベンゼン−1,5−ジアミン誘導体、その製造方法および医薬品における使用 | |
WO2014100533A1 (en) | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS | |
CN113683616A (zh) | Kras g12c突变蛋白抑制剂 | |
CN110167941A (zh) | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 | |
TW202003496A (zh) | 一種新穎磷酸肌醇3 - 激酶抑制劑及其製備方法和用途 | |
CN104837844A (zh) | 作为酪蛋白激酶1 d/e抑制剂的吡唑取代的咪唑并哌嗪 | |
CN112110938A (zh) | 一种作为蛋白质激酶抑制剂的化合物及其制备方法和用途 | |
CN106795152A (zh) | 蛋白激酶抑制剂 | |
CN104804001B9 (zh) | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 | |
CN113527300B (zh) | 布鲁顿酪氨酸蛋白激酶抑制剂 | |
CN108676009B (zh) | 作为her2酪氨酸激酶抑制剂的嘧啶衍生物及其应用 | |
EP3992193A1 (en) | Pyrazolopyrimidine compound, preparation method for same, and applications thereof | |
CN115490671B (zh) | Parp7抑制剂及其制备方法 | |
CN109641909A (zh) | 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用 | |
CN114907350B (zh) | 一类含氮稠环类化合物、制备方法和用途 | |
CN104640862B (zh) | 新的杂芳基和杂环化合物、其组合物及方法 | |
CA3234429A1 (en) | Ras inhibitors, compositions and methods of use thereof | |
CN105541792B (zh) | 多环类pi3k抑制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210908 Address after: 200233 room 701, building 1, No. 58, Yuanmei Road, Minhang District, Shanghai Patentee after: Shanghai Xucheng Pharmaceutical Technology Co.,Ltd. Address before: Xuanwu District of Nanjing City, Jiangsu province 210016 former banshanyuan No. 12 Building 1 layer 1 Patentee before: JIANGSU CAREPHAR PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
CI03 | Correction of invention patent |
Correction item: Claims|Description Correct: Claims 1-10 submitted on January 11, 2022|Paragraphs 1-326 of the specification submitted on January 11, 2022 False: Claims 1-10 submitted on July 21, 2017|Paragraphs 1-318 of the specification submitted on the application date Number: 37-01 Page: ?? Volume: 33 |
|
CI03 | Correction of invention patent |